Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ivonescimab
Pharma
Akeso details ivonescimab's 1st overall survival win
The addition of ivonescimab to chemotherapy reduced the risk of death by 26% in patients with EGFR-mutated NSCLC who had tried an EGFR inhibitor.
Angus Liu
Nov 7, 2025 11:30am
Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC
Oct 19, 2025 10:45am
Editor's Corner—Summit must submit to Big Pharma, stat
Sep 10, 2025 2:50pm
Summit's global PD-1xVEGF data show new promising OS trend
Sep 7, 2025 3:30am
Akeso, Summit's PD-1xVEGF drug meets OS goal for the first time
Aug 26, 2025 11:36am
Summit skips quarterly investor call as deal rumors swirl
Aug 12, 2025 10:29am
